Anxiety Disorder Treatment Guidelines
Primary Recommendations
- The Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology recommends SSRIs as the suggested pharmacotherapy for social anxiety disorder in adults, with a Number Needed to Treat (NNT) of 4.70, indicating robust therapeutic effect across multiple anxiety disorder subtypes, including generalized anxiety disorder, social anxiety disorder, panic disorder, and PTSD 1, 3, 4.
- Sertraline and escitalopram are the preferred first-line SSRIs based on efficacy, safety profile, and minimal drug interactions, with treatment response rates superior to buspirone, particularly when considering long-term outcomes 2, 4, 5.
Clinical Efficacy and Safety
- SSRIs produce significant improvements in anxiety symptoms, with SSRIs demonstrating stronger evidence as first-line treatment for anxiety disorders, and having dropout rates similar to placebo, indicating excellent tolerability despite noteworthy side effects 2, 4.
- Common SSRI side effects include gastrointestinal symptoms, headache, and sexual dysfunction, but these are generally manageable, and SSRIs do not cause physical dependence or withdrawal in the same manner as benzodiazepines, making them safer for long-term use 5, 6.
Treatment Algorithm
- The American College of Psychiatrists recommends initiating sertraline or escitalopram at a subtherapeutic "test" dose to minimize initial anxiety or agitation, with gradual titration at 1-2 week intervals until optimal benefit-to-harm ratio is achieved, and assessing response at 6 weeks for clinically significant improvement 4, 5, 6.
- If SSRI fails or is not tolerated, switching to an alternative SSRI or considering venlafaxine (SNRI) as second-line pharmacotherapy with NNT of 4.94, comparable to SSRIs, is recommended, with the addition of cognitive behavioral therapy to medication showing superior outcomes to either treatment alone 2, 4, 5, 6.